CVFG LLC’s AbbVie ABBV Stock Holding History

CVFG LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.31M	Sell	17,137 -2,524	-13%	-$543K	0.45%	64
2026 Q1	$4.28M	Buy	19,661 +18,261	+1,304%	+$4.05M	0.53%	58
2025 Q4	$320K	Sell	1,400 -52	-4%	-$11.8K	0.22%	78
2025 Q3	$336K	Buy	1,452 +32	+2%	+$6.52K	0.24%	74
2025 Q2	$263K	Buy	1,420 +1	+0.1%	+$186	0.21%	84
2025 Q1	$297K	Hold	1,419	–	–	0.27%	72
2024 Q4	$252K	Buy	+1,419	New	+$261K	0.23%	77

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

CVFG LLC's ABBV Position: Q2 2026 in Review

CVFG LLC reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $543K and leaving 17,137 shares worth $4.31M. The position accounts for 0.45% of the portfolio, ranked #64.

CVFG LLC first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

CVFG LLC held 17,137 shares of AbbVie worth $4.31M as of Q2 2026.
CVFG LLC sold 2,524 AbbVie shares in Q2 2026, an estimated $543K.
AbbVie made up 0.45% of CVFG LLC's portfolio in Q2 2026, its #64 holding.
CVFG LLC first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on CVFG LLC's 13F filing for Q2 2026, filed 11 Aug 2026.